Jiang Fanli, Yin Shi, Zhang Xinjin
Department of Cardiology, The Affiliated Hospital of Yunnan University, Kunming, China.
Front Genet. 2025 Mar 19;16:1548147. doi: 10.3389/fgene.2025.1548147. eCollection 2025.
The relationship between diabetic retinopathy (DR) and coronary artery disease (CHD) has been established as a reliable predictor. However, the underlying mechanisms linking these two conditions remain poorly understood. Identifying common key genes could provide new therapeutic targets for both diseases.
Public databases were used to compile training and validation datasets for DR and CHD. Machine learning algorithms and expression validation were employed to identify these key genes. To investigate immune cell differences, single-sample gene set enrichment analysis (ssGSEA) and the Wilcoxon test were applied. Spearman correlation analysis further explored the relationship between key genes and immune cell variations. Additionally, potential therapeutic drugs targeting these key genes were identified and a key gene-drug network was constructed. The role of the key genes in the pathogenesis of DR and CHD was further examined through reverse transcription-quantitative polymerase chain reaction (RT-qPCR).
Consistent expression trends observed across datasets (GSE221521, GSE113079, GSE189005, GSE42148) led to the identification of and as key genes. In GSE221521, HIRIP3 was positively correlated with CD56 bright natural killer cells (cor = 0.329, P < 0.001) and type 1T helper cells (cor = 0.327, P < 0.001), while showed significant correlations with CD4 T cell activation (cor = 0.340, P < 0.001) and type 1T helper cells (cor = 0.273, P < 0.05). Moreover, 82 transcription factors (TFs) were predicted, including SP3. Binding free energy calculations for key genes and potential drugs suggested stable binding conformations. RT-qPCR results revealed elevated expression of both and in the control group compared to the DR with CHD (DRwCHD) group, with only showing significant differences between the groups (p < 0.05).
These findings highlight and as crucial genes in DR and CHD detection, providing a foundation for identifying novel therapeutic targets for both diseases.
糖尿病视网膜病变(DR)与冠状动脉疾病(CHD)之间的关系已被确认为一种可靠的预测指标。然而,连接这两种病症的潜在机制仍知之甚少。识别共同的关键基因可为这两种疾病提供新的治疗靶点。
利用公共数据库汇编DR和CHD的训练和验证数据集。采用机器学习算法和表达验证来识别这些关键基因。为研究免疫细胞差异,应用了单样本基因集富集分析(ssGSEA)和威尔科克森检验。斯皮尔曼相关性分析进一步探讨了关键基因与免疫细胞变化之间的关系。此外,确定了靶向这些关键基因的潜在治疗药物,并构建了关键基因-药物网络。通过逆转录定量聚合酶链反应(RT-qPCR)进一步研究关键基因在DR和CHD发病机制中的作用。
在各数据集(GSE221521、GSE113079、GSE189005、GSE42148)中观察到的一致表达趋势导致将 和 鉴定为关键基因。在GSE221521中,HIRIP3与CD56明亮自然杀伤细胞呈正相关(cor = 0.329,P < 0.001)和1型辅助性T细胞呈正相关(cor = 0.327,P < 0.001),而 与CD4 T细胞活化呈显著相关性(cor = 0.340,P < 0.001)和1型辅助性T细胞呈显著相关性(cor = 0.273,P < 0.05)。此外,预测了82种转录因子(TFs),包括SP3。关键基因与潜在药物的结合自由能计算表明存在稳定的结合构象。RT-qPCR结果显示,与糖尿病合并冠心病(DRwCHD)组相比,对照组中 和 的表达均升高,只有 在两组之间存在显著差异(p < 0.05)。
这些发现突出了 和 在DR和CHD检测中的关键基因地位,为确定这两种疾病的新型治疗靶点奠定了基础。